Citadel Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-79,600
| Closed | -$465K | – | 16076 |
|
|
2022
Q4 | $465K | Sell |
79,600
-20,600
| -21% | -$108K | ﹤0.01% | 8394 |
|
|
2022
Q3 | $671K | Buy |
100,200
+53,300
| +114% | +$323K | ﹤0.01% | 7825 |
|
|
2022
Q2 | $197K | Buy |
46,900
+32,600
| +228% | +$129K | ﹤0.01% | 10716 |
|
|
2022
Q1 | $48K | Sell |
14,300
-11,200
| -44% | -$35.5K | ﹤0.01% | 12822 |
|
|
2021
Q4 | $80K | Buy |
25,500
+6,700
| +36% | +$22.3K | ﹤0.01% | 12946 |
|
|
2021
Q3 | $61K | Sell |
18,800
-20,300
| -52% | -$71.1K | ﹤0.01% | 13258 |
|
|
2021
Q2 | $165K | Sell |
39,100
-26,100
| -40% | -$110K | ﹤0.01% | 12399 |
|
|
2021
Q1 | $325K | Buy |
65,200
+45,900
| +238% | +$371K | ﹤0.01% | 10665 |
|
|
2020
Q4 | $244K | Sell |
19,300
-2,900
| -13% | -$33.1K | ﹤0.01% | 9438 |
|
|
2020
Q3 | $218K | Buy |
22,200
+500
| +2% | +$4.93K | ﹤0.01% | 8676 |
|
|
2020
Q2 | $216K | Buy |
+21,700
| New | +$208K | ﹤0.01% | 8417 |
|
|
2019
Q2 | – | Sell |
-12,800
| Closed | -$154K | – | 10080 |
|
|
2019
Q1 | $154K | Buy |
+12,800
| New | +$189K | ﹤0.01% | 8376 |
|
|
2016
Q1 | – | Sell |
-1,200
| Closed | -$23K | – | 8292 |
|
|
2015
Q4 | $23K | Buy |
+1,200
| New | +$26.1K | ﹤0.01% | 7842 |
|
Citadel Advisors's CNCE Position: Q1 2023 in Review
Citadel Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,391,302 shares — an estimated $8.13M sold.
Citadel Advisors first reported a position in CNCE in Q4 2014 and held it in 24 quarters. The position peaked at $8.13M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Citadel Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 1,391,302 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $8.13M.
- Citadel Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 24 quarters.
- Citadel Advisors's Concert Pharmaceuticals, Inc. position peaked at $8.13M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.